摘要
目的:探讨参苓白术散治疗新型冠状病毒肺炎(COVID-19)恢复期肺脾气虚证的潜在作用机制及可行性。方法:使用中药数据库筛选参苓白术散的活性成分并预测靶点;运用Cytoscape构建和分析网络;通过靶点间蛋白质相互作用网络提取重要靶点;对重要靶点行生物功能及通路进行富集分析;用iGEMDOCK进行分子对接实验。结果:纳入127种参苓白术散所含活性成分,预测到193个靶点,核心成分为二氢槲皮素、山柰酚和木犀草素等。26个重要靶点富集在免疫炎症反应(白细胞介素17、B细胞及肿瘤坏死因子等通路)、血管紧张素对循环系统的调节和肾上腺素能等神经-内分泌相关功能。5个核心成分具有与COVID-19靶点结合的潜能。结论:参苓白术散可能通过作用于免疫炎症反应、循环及神经-内分泌相关信号通路,结合调理肠道菌群,从而治疗COVID-19恢复期肺脾气虚证。
OBJECTIVE:To probe into the potential mechanism and feasibility of Shenling Baizhu powder in the treatment of Qi-deficiency of lung and spleen of COVID-19 in recovery phase.METHODS:Use the Chinese medicine database to screen the active ingredients of Shenling Baizhu powder and predict the targets;use Cytoscape to construct and analyze the network;to extract important targets through the protein interaction network among targets;to perform biological function and pathway enrichment analyses on important targets;and to conduct molecular docking experiment through iGEMDOCK.RESULTS:Totally 127 kinds of active ingredients were contained in Shenling Baizhu powder,193 targets were predicted,and the core ingredients were dihydroquercetin,kaempferol and luteolin.26 important targets were enriched in neuro-endocrine related functions including immune-inflammatory response(pathways of interleukin 17,B cells and tumor necrosis factor),regulation of angiotensin on circulatory system,and adrenergic.Of which 5 core ingredients had the potential to bind to COVID-19 targets.CONCLUSIONS:Shenling Baizhu powder may act on the immune-inflammatory response,circulation and neuro-endocrine related signal pathways,combined with regulating the intestinal flora,so as to treat the Qi-deficiency of lung and spleen of COVID-19 in recovery phase.
作者
林彤
李丽
梁彩君
曾辉
李晓良
彭立生
LIN Tong;LI Li;LIANG Caijun;ZENG Hui;LI Xiaoliang;PENG Lisheng(The Fourth Clinical Medical School,Guangzhou University of Chinese Medicine,Guangdong Shenzhen 518033,China;Dept.of Internal Medicine-Cardiovascular,the Third People’s Hospital of Shenzhen,Guangdong Shenzhen 518033,China;Dept.of Science and Education,Shenzhen Hospital of Traditional Chinese Medicine,Guangdong Shenzhen 518033,China)
出处
《中国医院用药评价与分析》
2020年第12期1433-1436,1441,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
广东省中医药局新冠肺炎中医药防治临床研究应急项目(No.2020ZYYJ15)。
